SELLAS Life Sciences Group, Inc. (SLS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Research Workspace
Put SLS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Overcome regulatory challenges from trial data: REGAL trial nears final analysis; 2026-Q4 approval target at risk.
View ThesisRevenue is contracting — down about 100% over the past year.
View GrowthManagement screens weak on capital allocation, the balance sheet.
View ManagementThis stock is volatile — it swings about 4% on a typical day and fell roughly 36% in its worst 12-month stretch.
View RiskSLS's growth relies on advancing clinical trial enrollment and topline data release. Recent financial performance has been weak, with a wider loss reported in Q2 FY2026. The stock trades at a Price-to-Book multiple of 19.7x, compared to a peer average of 14.1x. This suggests that high expectations for its pipeline potential are priced in. If SLS cuts guidance on the next call, it could negatively impact the stock. The thesis is on watch due to regulatory challenges from the REGAL trial nearing final analysis. This read is provisional.
Trailing returns as of 2026-09-04. SLS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering SLS (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare SLS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SLS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put SLS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Advance clinical trial enrollment and topline data release
Stock drop indicates concerns over clinical trial progress.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Advances: Advance clinical trial enrollment and topline data release
Key trial progress supports clinical trial enrollment objective.

Threatens: Manage operating expenses and cash burn
Wider loss indicates challenges in managing operating expenses.

REGAL readout inconsistency raises concerns about regulatory approval.
REGAL delay suggests potential issues with clinical trial outcomes.